JLPC(SH:600513) Sou Hu Cai Jing·2026-02-06 09:48Group 1 - The company, Lianhuan Pharmaceutical (600513.SH), plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB, raising it from 131.52 million RMB to 181.52 million RMB [1] - The purpose of this capital increase is to support the strategic development plan of Lianhuan (Anqing) and to meet its funding needs for product research and development, license acquisition, and production line upgrades [1] - This capital increase does not involve related party transactions, does not constitute a major asset restructuring, and does not require approval from the company's shareholders [1] Group 2 - The completion of the capital increase is subject to approval from the relevant state-owned asset authorities, indicating a regulatory requirement [1] - There is uncertainty regarding the operational status and profitability of Lianhuan (Anqing) following the capital increase [1]